The Boeing Company (NYSE:BA) released that Polish charter carrier Enter Air has placed an order for two 737 MAX 8s as well as two Next-Generation 737-800s. The order, valued over $400M at present list prices and previously attributed to an unidentified customer, is the first direct order for Boeing from Enter Air. The firm articulated that 737 MAX incorporates the newest technology CFM International LEAP-1B engines, Advanced Technology winglets and other improvements. The 737 MAX has accumulated over 2,800 orders to date from 58 customers. Grzegorz Polaniecki, CEO of Enter Air, said, “With this latest acquisition we will be able to boost our expansion across the European holiday market, offering our clients competitive pricing with exceptional comfort.” The Boeing Company (NYSE:BA) stock price closed at $145.13 with the total traded volume of 4.78 Million shares. Its price to sales ratio ended at 1.09. Its market capitalization is 100.36 Billion. The stock owned by the Financial Institutions was 75.50% while by insiders was 0.20%.
Amgen Inc. (NASDAQ:AMGN) released that a Phase 3 study evaluating Vectibix or panitumumab and best supportive care or BSC met its primary endpoint, demonstrating a statistically significant development in in general endurance or OS in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer or mCRC as compared to those patients treated with BSC alone. The Vectibix treatment arm further illustrated statistical significance for all key secondary endpoints including OS in patients with wild-type RAS (absence of mutations in exons 2, 3 and 4 of KRAS and NRAS) mCRC. M.D., executive VP of Research and Development at Amgen, Sean Harper stated that Amgen has been at the forefront of researching personalized approaches to treating cancer, as well as the Vectibix clinical program continues to underscore the importance of identifying options for patients based on their cancer’s genetic makeup. Amgen Inc. (NASDAQ:AMGN) has the market capitalization of 122.20 Billion. Shares of firm moved up 0.37% to close at $160.72 with the total traded volume of 5.17 Million. The firm has current ratio of 5.50 for the most recent quarter.
Microchip Technology Inc. (NASDAQ:MCHP) released that in connection with the previously released that definitive contract under which Microchip will buy Micrel Inc. (MCRL), the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, had expired on June 15, 2015, as well as the Federal Cartel Office in Germany had cleared the transaction on June 17, 2015. There is no further antitrust clearance purchased for closure of the transaction. Completion of the merger remains subject to certain additional closing conditions, comprising endorsement by Micrel shareholders of the merger. The special meeting of Micrel shareholders to approve the merger has not yet been set. Microchip Technology Inc. (NASDAQ:MCHP) begun last trade with a price of $49.160 and throughout the trading session climbed at a high of $49.820. The day-trade ended with 1.34% to $49.67. The stock is going forward to its 52 week low with 37.59% and lagging behind from its 52 week high price with -4.59%. it’s month stock price volatility remained 1.77%.